共 247 条
[1]
Johnell O(2006)An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 1726-1733
[2]
Kanis JA(2013)The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data Dtsch Arztebl Int 110 52-57
[3]
Hadji P(2005)Bisphosphonates: providing strength to a significant class Manag Care 14 24-28
[4]
Klein S(2009)Adverse effects of bisphosphonates: implications for osteoporosis management Mayo Clin Proc 84 632-637
[5]
Gothe H(2009)Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL J Bone Miner Res 24 182-195
[6]
Haussler B(2004)Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases JAMA 292 490-495
[7]
Kless T(2012)GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates Osteoporos Int 23 223-231
[8]
Schmidt T(2009)Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis Patient Prefer Adh 3 25-30
[9]
Steinle T(2007)A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis Curr Med Res Opin 23 585-594
[10]
Verheyen F(2008)Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case–control analysis Clin Ther 30 2410-2422